(Q44457418)

3 December 2017

title

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial (English)

1 reference

3 December 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Anthony F Shields

1

1 reference

3 December 2017

Mark M Zalupski

series ordinal

2

1 reference

3 December 2017

John L Marshall

series ordinal

3

1 reference

3 December 2017

Neal J Meropol

series ordinal

4

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

3 December 2017

1 reference

3 December 2017

volume

100

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

531-537

1 reference

3 December 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Oxaliplatin clinical activity: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11925

7 January 2021

Identifiers

DOI

10.1002/CNCR.11925

1 reference

3 December 2017

1 reference